Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals

Executive Summary

After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.
Advertisement

Related Content

Hips Don’t Lie: J&J Faces Compensation Maelstrom In India Over Faulty ASR Implants
Dapagliflozin Alliance Targets Surging Indian Diabetes Market
Forxiga debuts in India at fraction of global prices
'Responsibly' priced Invokana debuts in India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel